Retinal glial cell glutamate transporter is coupled to an anionic conductance.

Por Eliasof, S, Jahr, C E
Publicado em 1996

CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development

Por Young, Cissy, Schluep, Thomas, Hwang, Jungyeon, Eliasof, Scott
Publicado em 2011

Mimetic Neural Networks: A Unified Framework for Protein Design and Folding

Por Moshe Eliasof, Tue Boesen , Eldad Haber , Chen Keasar , Eran Treister 
Publicado em 2022-05-01

Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance

Por Arriza, Jeffrey L., Eliasof, Scott, Kavanaugh, Michael P., Amara, Susan G.
Publicado em 1997

Sulfhydryl modification of V449C in the glutamate transporter EAAT1 abolishes substrate transport but not the substrate-gated anion conductance

Por Seal, Rebecca P., Shigeri, Yasushi, Eliasof, Scott, Leighton, Barbara H., Amara, Susan G.
Publicado em 2001

WAY-855 (3-amino-tricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid): a novel, EAAT2-preferring, nonsubstrate inhibitor of high-affinity glutamate uptake

Por Dunlop, John, Eliasof, Scott, Stack, Gary, McIlvain, H Beal, Greenfield, Alexander, Kowal, Dianne, Petroski, Robert, Carrick, Tikva
Publicado em 2003

CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF-1α

Por Tian, Xi, Nguyen, Minh, Foote, Henry P., Caster, Joseph M., Roche, Kyle C., Peters, Christian G., Wu, Pauline, Jayaraman, Lata, Garmey, Edward G., Tepper, Joel E., Eliasof, Scott, Wang, Andrew Z.
Publicado no Cancer Res (2016)

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Por Eliasof, Scott, Lazarus, Douglas, Peters, Christian G., Case, Roy I., Cole, Roderic O., Hwang, Jungyeon, Schluep, Thomas, Chao, Joseph, Lin, James, Yen, Yun, Han, Han, Wiley, Devin T., Zuckerman, Jonathan E., Davis, Mark E.
Publicado em 2013

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical tr...

Por Keefe, S. M., Hoffman-Censits, J., Cohen, R. B., Mamtani, R., Heitjan, D., Eliasof, S., Nixon, A., Turnbull, B., Garmey, E. G., Gunnarsson, O., Waliki, M., Ciconte, J., Jayaraman, L., Senderowicz, A., Tellez, A. B., Hennessy, M., Piscitelli, A., Vaughn, D., Smith, A., Haas, N. B.
Publicado no Ann Oncol (2016)